Sargent Bickham Lagudis’s United Therapeutics UTHR Stock Holding History

Sargent Bickham Lagudis’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,444	Closed	-$152K	–	782
2019 Q2	$152K	Hold	2,444	–	–	0.02%	229
2019 Q1	$152K	Hold	2,444	–	–	0.02%	240
2018 Q4	$152K	Hold	2,444	–	–	0.02%	228
2018 Q3	$152K	Hold	2,444	–	–	0.02%	233
2018 Q2	$152K	Hold	2,444	–	–	0.02%	231
2018 Q1	$152K	Hold	2,444	–	–	0.02%	239
2017 Q4	$152K	Hold	2,444	–	–	0.02%	242
2017 Q3	$152K	Hold	2,444	–	–	0.02%	241
2017 Q2	$152K	Hold	2,444	–	–	0.02%	231
2017 Q1	$152K	Hold	2,444	–	–	0.02%	236
2016 Q4	$152K	Hold	2,444	–	–	0.02%	227
2016 Q3	$152	Hold	2,444	–	–	0.02%	232
2016 Q2	$152K	Hold	2,444	–	–	0.02%	234
2016 Q1	$152K	Buy	+2,444	New	+$309K	0.02%	235

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sargent Bickham Lagudis's UTHR Position: Q3 2019 in Review

Sargent Bickham Lagudis sold out of United Therapeutics (UTHR) in Q3 2019, closing a stake of 2,444 shares — an estimated $152K sold.

Sargent Bickham Lagudis first reported a position in UTHR in Q1 2016 and held it in 14 quarters. The position peaked at $152K in Q2 2019. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

Sargent Bickham Lagudis reported no remaining United Therapeutics position as of Q3 2019 after selling out during the quarter.
Sargent Bickham Lagudis sold 2,444 United Therapeutics shares in Q3 2019, an estimated $152K.
Sargent Bickham Lagudis first reported a position in United Therapeutics in Q1 2016 and held it in 14 quarters.
Sargent Bickham Lagudis's United Therapeutics position peaked at $152K in Q2 2019.
302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2019, filed 14 Sep 2021.